4. Other information
4.1 Significant shareholders
The Board of Directors is not aware of any major shareholder with a holding exceeding 3% of all votes as at December 31, 2020 and 2019.
4.2 Statement of holdings of the Board of Directors
As at December 31, the Board of Directors held the following registered shares of BB Biotech AG:
|
|
|
2020 |
|
2019 |
|
Dr. Erich Hunziker, Chairman |
|
957 884 |
|
1 457 884 |
|
Dr. Clive Meanwell, Vice-Chairman |
|
5 163 |
|
5 163 |
|
Dr. Susan Galbraith |
|
– |
|
– |
|
Prof. Dr. Mads Krogsgaard Thomsen |
|
– |
|
– |
|
Dr. Thomas von Planta |
|
12 000 |
|
12 000 |
4.3 Management contracts
On behalf of the Company, the Board of Directors has entered into a management contract with Bellevue Asset Management AG (investment manager). In this contract, the investment manager commits to carry out management services relating to the investment activity and management of BB Biotech AG. Under this contract the Company paid in the business year 2020 CHF 723 837 (2019: CHF 737 585) to Bellevue Asset Management AG.
4.4 Annual report and cash flow statement
Due to the fact that BB Biotech AG prepares consolidated financial statements in accordance with a recognized international accounting standard (IFRS), the Company doesn’t prepare, in line with the legal requirements, an annual report and cash flow statement.